Skip to main content
    H

    Heron Therapeuti (HRTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.28
    -0.03 (-8.44%)

    Market Cap: $59.08M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Heron Therapeuti (HRTX) Earnings: Report Dates and Results

    Updated Nov 9, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    In the quarter ended Sep 30, 2026, Heron Therapeuti reported EPS of -$0.03, in line with the -$0.03 estimate. It beat the EPS estimate in 3 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    45%(18/40)
    Avg Surprise
    -2.77%

    Upcoming Estimates

    Report date not yet scheduledPeriod ending Dec 31, 2026
    EPS Consensus-$0.03
    Range-$0.04 - -$0.02
    4 analysts
    Revenue Consensus
    $34.68M
    Range$30.87M - $38.33M
    4 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS ConsensusN/A
    RangeN/A
    Revenue Consensus
    N/A
    RangeN/A
    0 analysts

    Next Report

    HRTX's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.

    HRTX Earnings Call

    The latest HRTX earnings call transcript on file is labeled 2026Q2.

    Read the 2026Q2 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, HRTX beat 18, missed 21 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $35.25M, down 7.7% from $38.21M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.03-$0.03-$0.03 - -$0.020.00%In lineN/A20 up, 1 downNov 9, 2026$35.25M
    Jun 30, 2026-$0.03-$0.02-$0.02 - -$0.02-50.00%MissN/A10 up, 0 downAug 10, 2026$37.67M
    Mar 31, 2026-$0.04-$0.02-$0.02 - -$0.02-100.00%Miss-500.0%10 up, 0 downMay 11, 2026$34.71M
    Dec 31, 2025-$0.02-$0.03-$0.03 - -$0.03+33.33%Beat-200.0%10 up, 0 downFeb 26, 2026$40.59M
    Sep 30, 2025-$0.04-$0.01-$0.02 - $0.00-300.00%MissN/A30 up, 0 downNov 4, 2025$38.21M
    Jun 30, 2025-$0.02-$0.01-$0.02 - $0.00-100.00%MissN/A30 up, 1 downAug 8, 2025$37.20M
    Mar 31, 2025$0.01-$0.01-$0.01 - -$0.01+200.00%BeatN/A20 up, 0 downMay 6, 2025$38.90M
    Dec 31, 2024$0.02-$0.03-$0.03 - -$0.02+180.00%BeatN/A21 up, 0 downFeb 27, 2025$40.78M
    Sep 30, 2024-$0.03-$0.04-$0.04 - -$0.03+25.00%BeatN/A30 up, 0 downNov 12, 2024$32.81M
    Jun 30, 2024-$0.06-$0.05-$0.05 - -$0.02-20.00%MissN/A40 up, 0 downAug 6, 2024$36.02M
    Mar 31, 2024-$0.02-$0.09-$0.11 - -$0.07+77.78%BeatN/A30 up, 0 downMay 7, 2024$34.67M
    Dec 31, 2023-$0.07-$0.15-$0.19 - -$0.13+53.33%BeatN/A30 up, 0 downMar 12, 2024$34.23M
    Sep 30, 2023-$0.17-$0.30-$0.33 - -$0.23+43.33%BeatN/A40 up, 0 downNov 14, 2023$31.43M
    Jun 30, 2023-$0.35-$0.23-$0.26 - -$0.19-52.17%MissN/A50 up, 0 downAug 14, 2023$31.76M
    Mar 31, 2023-$0.27-$0.20-$0.25 - -$0.13-35.00%MissN/A40 up, 0 downMay 11, 2023$29.61M
    Dec 31, 2022-$0.17-$0.28-$0.38 - -$0.12+39.29%BeatN/A40 up, 0 downMar 23, 2023$30.03M
    Sep 30, 2022-$0.38-$0.39-$0.44 - -$0.30+2.56%BeatN/A50 up, 0 downNov 8, 2022$26.56M
    Jun 30, 2022-$0.55-$0.54-$0.59 - -$0.37-1.85%MissN/A50 up, 0 downAug 9, 2022$27.63M
    Mar 31, 2022-$0.63-$0.52-$0.56 - -$0.30-21.15%MissN/A50 up, 0 downMay 9, 2022$23.46M
    Dec 31, 2021-$0.54-$0.58-$0.62 - -$0.51+6.90%BeatN/A50 up, 0 downFeb 28, 2022$20.66M
    Sep 30, 2021-$0.51-$0.60-$0.68 - -$0.56+15.00%BeatN/A50 up, 0 downNov 3, 2021$23.23M
    Jun 30, 2021-$0.62-$0.57-$0.61 - -$0.49-8.77%MissN/A5N/AAug 9, 2021$22.44M
    Mar 31, 2021-$0.58-$0.53-$0.65 - -$0.48-9.43%MissN/A6N/AMay 10, 2021$20.02M
    Dec 31, 2020-$0.68-$0.65-$0.90 - -$0.50-4.62%MissN/A7N/AFeb 24, 2021$20.61M
    Sep 30, 2020-$0.64-$0.62-$0.75 - -$0.51-3.23%MissN/A7N/ANov 5, 2020$19.96M
    Jun 30, 2020-$0.61-$0.60-$0.83 - -$0.55-1.67%MissN/A8N/AAug 5, 2020$22.67M
    Mar 31, 2020-$0.57-$0.67-$0.76 - -$0.56+14.93%BeatN/A8N/AMay 6, 2020$25.40M
    Dec 31, 2019-$0.65-$0.56-$0.72 - -$0.45-16.07%MissN/A9N/AMar 2, 2020$35.08M
    Sep 30, 2019-$0.42-$0.58-$0.69 - -$0.48+27.59%BeatN/A9N/ANov 12, 2019$42.62M
    Jun 30, 2019-$0.63-$0.62-$0.77 - -$0.49-1.61%MissN/A10N/AAug 5, 2019$36.66M
    Mar 31, 2019-$0.80-$0.50-$0.64 - -$0.28-60.00%MissN/A9N/AMay 9, 2019$31.60M
    Dec 31, 2018-$0.63-$0.46-$0.56 - -$0.37-36.96%MissN/A9N/AFeb 22, 2019$28.84M
    Sep 30, 2018-$0.49-$0.44-$0.60 - -$0.29-11.36%MissN/A9N/ANov 7, 2018$19.79M
    Jun 30, 2018-$0.54-$0.68-$0.93 - -$0.53+20.59%BeatN/A10N/AAug 8, 2018$17.28M
    Mar 31, 2018-$0.81-$0.88-$1.07 - -$0.44+7.95%BeatN/A12N/AMay 10, 2018$11.57M
    Dec 31, 2017-$1.09-$0.79-$0.91 - -$0.69-37.97%MissN/A11N/AFeb 27, 2018$10.05M
    Sep 30, 2017-$0.77-$0.86N/A+10.47%BeatN/AN/AN/ANov 6, 2017$8.57M
    Jun 30, 2017-$0.80-$0.91N/A+12.09%BeatN/AN/AN/AAug 9, 2017$8.51M
    Mar 31, 2017-$1.00-$0.91N/A-9.89%MissN/AN/AN/AMay 10, 2017$3.63M
    Dec 31, 2016-$1.22-$1.23N/A+0.81%BeatN/AN/AN/AFeb 23, 2017$1.28M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.07, after -$0.09 the year before. It was -$4.55 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.07N/A
    Dec 31, 2024-$0.09N/A
    Dec 31, 2023-$0.86N/A
    Dec 31, 2022-$1.73N/A
    Dec 31, 2021-$2.25N/A
    Dec 31, 2020-$2.50N/A
    Dec 31, 2019-$2.50N/A
    Dec 31, 2018-$2.47N/A
    Dec 31, 2017-$3.66N/A
    Dec 31, 2016-$4.55N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 2,700 words across 7 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q2Jun 30, 20262,7017
    2026Q1Mar 31, 20265,0219
    2025Q4Dec 31, 20253,9089
    2025Q3Sep 30, 20254,10611
    2025Q2Jun 30, 20253,7149
    2025Q1Mar 31, 20253,2407
    2024Q4Dec 31, 20243,8659
    2024Q3Sep 30, 20243,6299

    2026Q2 Earnings Call

    Opening remarks

    Melissa Jarel Investor Relations Thank you, Operator, and good morning, everyone. Thank you for joining us on the Heron Therapeutics conference call today to discuss the company's financial results for the second quarter of 2026. With me today from Heron are Craig Collard, Chief Executive Officer; Ira Duarte, Executive Vice President, Chief Financial Officer; Bill Forbes, Executive Vice President, Chief Development Officer; Mark Hensley, Chief Operating Officer; and Kevin Warner, Senior Vice President, Medical Affairs Strategy and Engagement. For those of you participating in the conference call, slides are made available via webcast and can also be accessed via the Investor Relations page of our website following the conclusion of today's call. Before we begin, let me quickly remind you that during the course of this conference call, the company will make forward-looking statements. We caution you that any statement that is not a statement of historical fact is a forward-looking statement. This includes remarks about the company's projections, expectations, plans, beliefs, and future performance, all of which constitute forward-looking statements for the purposes of the Safe Harbor Provision under the Private Securities Litigation Reform Act of 1995. These statements are based on judgment and analysis as of the date of this conference call and are subject to numerous important risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties associated with the forward-looking statements made in this conference call and webcast are described in the Safe Harbor statement in today's press release and in Heron's public periodic filings with the SEC. Except as required by law, Heron assumes no obligation to update these forward-looking statements to reflect future events or actual outcomes and does not intend to do so. And with that, I would now like to turn the call over to Craig Collard, Chief Executive Officer of Heron.

    Craig Collard Chief Executive Officer Thanks, Melissa. Hello, everyone, and welcome to Heron Therapeutics' second quarter 2026 earnings call. Net revenue for the quarter was $37.7 million. That is growth from the first quarter, but it is below what we expected of ourselves. CINVANTI sales were up compared to Q1 in a highly competitive market, and ZYNRELEF grew 35% year-over-year, but both were slower than we anticipated. Turning to Slide 4, let me walk through the key updates from the quarter. The acute care franchise delivered revenue growth of 44% year-over-year. ZYNRELEF grew 35%, with average daily units growing 19% year-over-year. APONVIE grew 74% year-over-year and reached 23% share of the surgical NK-1 segment, up 2 points from the first quarter. And CINVANTI came in at $21.8 million, up from $20.5 million in the first quarter.

    Frequently Asked Questions About HRTX

    Did HRTX beat earnings estimates last quarter?

    Heron Therapeuti reported EPS of -$0.03 for the quarter ended Sep 30, 2026, in line with the -$0.03 estimate.

    What EPS do analysts expect from HRTX next quarter?

    The consensus EPS estimate for Heron Therapeuti for the quarter ending Dec 31, 2026 is -$0.03 from 4 analysts, with estimates from -$0.04 to -$0.02.

    How often does HRTX beat earnings estimates?

    Heron Therapeuti beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -17.08%.